Clinical trials: Measles Infection
Rubella, Measles
Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella
Measles and rubella are highly contagious acute viral diseases. As per WHO, several evidences demonstrate the benefit for providing the universal access to vaccines containing measles and rubella antigens, mainly due to…
- Trial name
- BIOMR (NCT03148990)
- Testing
- Measles and Rubella vaccine, Measles, Mumps and Rubella vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Japanese Encephalitis
Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and…
- Trial name
- JEV03 (NCT00463684)
- Testing
- Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine, Live, attenuated measles vaccine
- Where
- 3 sites in Sri Lanka
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- PATH
Mumps
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
The purpose of this study is to evaluate the safety and immunogenicity of mumps vaccine in healthy infants aged 8-12months, compared with measles, mumps and rubella combined vaccine, live (MMRV).
- Trial name
- NCT04364399
- Testing
- Mumps vaccine, measles, mumps and rubella combined vaccine, live
- Where
- China
- Volunteers
- 920 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Measles
Early Two-dose Measles Vaccination Trial
The specific aims are to examine in Guinea-Bissau: whether the standard titre Schwarz (SW) or standard-titre Edmonston-Zagreb (EZ) measles vaccine will be the best vaccine strain for use in a routine one-dose measles vaccination…
- Trial name
- NCT00168558
- Testing
- Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 5,879 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Measles, Mumps
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00109343
- Testing
- Comparator: ProQuad™ (V221), Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
- Volunteers
- 1,027 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00351923
- Testing
- MeMuRu-OKA (study vaccine)
- Where
- 20 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
Primary objective: To compare if, when given concomitantly with VARIVAX® by the same route at 12-18 months of age using separate injection sites, a single dose of M-M-RTMII administered by IM route is as immunogenic as a single…
- Conditions
- Measles, Mumps, Varicella
- Trial name
- NCT00432523
- Testing
- M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
- Where
- 2 sites in France, Germany
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mumps, Rubella
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00126997
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 54 sites in Finland, Germany and 2 more
- Volunteers
- 1,439 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Tract Infections, Infections
Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children
The goal of this clinical trial is to evaluate the off-target/non-specific effects of the measles-mumps-rubella (MMR) vaccine in children.
- Conditions
- Respiratory Tract Infections, Infections, Allergy, Eczema
- Trial name
- NEMAU (NCT05758532)
- Testing
- Measles-Mumps-Rubella vaccine (MMR)
- Where
- Switzerland
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Laure Pittet, MD-PhD
Congenital Rubella Infection, Measles
Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
Thus study is a clinical trial for Measles and Rubella vaccine that will be used inIndonesian National Program of Immunization. The study design will be randomized, observer blind, prospective intervention study.
- Trial name
- NCT04183114
- Testing
- Measles-Rubella vaccine Bio Farma, MR Vaccine SII
- Where
- Indonesia
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Measles, Polio
A Tool Kit to Improve Vaccine Confidence in the Philippines
This cluster randomized controlled trial (RCT) aims to evaluate the feasibility and efficacy of an educational toolkit in enhancing measles, mumps, rubella (MMR) and polio vaccine confidence in the Philippines.
- Conditions
- Measles, Polio, Vaccination Hesitancy
- Trial name
- NCT06218368
- Testing
- Educational toolkit on MMR and polio vaccination
- Where
- Philippines
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Rubella, Varicella
Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration…
- Conditions
- Rubella, Varicella, Mumps, Measles
- Trial name
- NCT00406211
- Testing
- MMRV, MMR (Priorix®), Varicella (Varilrix®)
- Where
- 41 sites in Austria, Germany
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
The purpose of this study is to demonstrate that an investigational refrigerated vaccine with measles, mumps, rubella, and varicella is well tolerated and has similar immune response when compared to a frozen vaccine with…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00092430
- Testing
- V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Rubella
Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
This is an open-label, randomized, 2-arm clinical trial in healthy infants in Bangladesh. The primary purpose of the study is to assess the immunogenicity of measles-rubella (MR) vaccine when delivered at 6 months.
- Conditions
- Measles, Rubella, Rubella Syndrome, Congenital
- Trial name
- NCT03071575
- Testing
- Measles-rubella (MR) vaccine at 6 months of age, Measles-rubella (MR) vaccine at 9 months of age
- Where
- Bangladesh
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Covid19
Measles Vaccine in HCW
Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is…
- Trial name
- MV-COVID19 (NCT04357028)
- Testing
- Measles-Mumps-Rubella Vaccine
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
Measles
Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years
Partially randomized, controlled Phase II study to evaluate safety, immunogenicity and dose response of the measles vaccine MVA mBN85B in healthy children aged 6 months to 6 years.
- Trial name
- NCT00891007
- Testing
- MVA-mBN85B, Rouvax
- Where
- South Africa
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Immunity, Measles
The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants
Background: It is well established that the presence of bacteria in the intestine has a profound influence on health. Probiotics, ("beneficial bacteria") have shown ameliorating effects on various infectious diseases.
- Conditions
- Immunity, Measles, Mumps, Rubella
- Trial name
- NCT00645996
- Testing
- Probiotics (L.acidophilus and B.lactis), Cornflor
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assaf-Harofeh Medical Center
Measles; Mumps; Rubella; Chickenpox, Measles
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
- Trial name
- NCT05630846
- Testing
- Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine
- Where
- 47 sites in United States, Colombia and 3 more
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunization Coverage, Vaccination
Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months
Provision of SQ-LNS also holds promise in incentivizing vaccination as well as other health services. The investigators will estimate 1) the effectiveness of a SQ-LNS mass supplementation program added to routine immunization…
- Conditions
- Immunization Coverage, Vaccination, Nutrition
- Trial name
- NCT06387511
- Testing
- Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax, Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices
- Where
- Nigeria
- Volunteers
- 3,814 people, healthy volunteers welcome
- Sponsor
- Alliance for International Medical Action
Diphtheria, Tetanus
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
The project goal is to conduct a randomized controlled trial (RCT) to test whether mobile phone short message system (SMS) reminders, either with or without mobile-phone based travel subsidies will improve timeliness, coverage…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- m-SIMU (NCT01878435)
- Testing
- SMS reminder, Travel subsidy, Travel subsidy 2
- Where
- Kenya
- Volunteers
- 2,018 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health